Treatment With A Carboplatin-Based Doublet Plus Bevacizumab Beyond Disease Progression Significantly Improved Progression-Free Survival Vs A Carboplatin-Based Doublet Alone In Women With Platinum-Sensitive Ovarian Cancer In Phase 3 Trial

The ASCO Post (2/23, Stenger) reports researchers found in the phase 3 MITO16b/MANGO-OV2/ENGOT-ov17 trial “found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease recurrence after first-line treatment with a platinum-based therapy plus bevacizumab.” The trial’s results were published in The Lancet Oncology.